clinical trial bpc 157 human BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire evidence base actually looks like, and the questions to ask next. — WellFounded bpc-157 clinical trial human dosing
Description
Hydroxocobalamin is usually found in injectable form, although injectable cyanocobalamin is also more common, with Optovite (cyanocobalamin) being the most common drug in Spain for this use

In turn, this may contribute to the development of depression by increasing oxidative stress, DNA damage, and cell death in the body ( A 2020 study with 132 children and teens, 89 with and 43 without depression, found that the participants with depression had lower B12 levels and higher levels of homocysteine compared with those without depression ( In addition to depressive symptoms, low or deficient B12 levels may lead to other mental conditions, including psychosis and mood disorders ( Because a deficiency in B12 negatively impacts the central nervous system, people with low or deficient B12 levels may feel foggy-headed and have difficulty concentrating and completing tasks ( Fortunately, studies show that mental impairment related to low B12 levels can improve with B12 treatment

BPC-157 itself has a very short half-life in the body (as low as 30 minutes)which, at first blush, would make it look like a dopers dream

Problems are more often linked to supplements, especially in high doses
